8. Eisai Ltd 2013. Zonegran Summary of Product Characteristics [http://www.medicines.org.uk/emc/medicine... ] (última actualización febrero de 2013)
9. Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551-63. doi: 10.1111/epi.12074. Epub 2013 Jan 25.
10. Pugliatti M et al. (2007). Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia, 48(12), 2224 - 2233.
Date of preparation: September 2013
Job code: Zonegran-UK2510b
CONTACTO: Consultas de los medios de comunicación: Eisai Europe Ltd:Cressida Robson/Charlotte Andrews, +44(0)7908 314 155/+44(0)7947 231 513,Cressida_Robson@eisai.net, Charlotte_Andrews@eisai.net; Tonic LifeCommunications: Frances Murphy/Nicola Lilley , +44(0)207 798 9262/+44 (0)207 798 9905 , frances.murphy@toniclc.com, nicola.lilley@toniclc.com
Andalucía
Aragón
Cantabria
Castilla-La Mancha
Castilla y León
Catalunya
Extremadura
Galicia
Islas Canarias
Islas Baleares
Madrid
País Vasco
La Rioja
C. Valenciana
Navarra
Asturias
Murcia
Ceuta y Melilla
.png)